Menu
Not yet recruiting NCT06960447

Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa

No phase Interventional Hidradenitis Suppurativa (HS)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Nd:YAG Laser, Alexandrite Laser.
Who it may be relevant to
Registry conditions: Hidradenitis Suppurativa (HS). Basic parameters: 12 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Comparative Efficacy of Nd:YAG and Alexandrite Laser Treatments in Hidradenitis Suppurativa: A Split-Person, Non-Inferiority Study

Overview

The purpose of this study is to evaluate whether Alexandrite laser treatment is non-inferior to Nd:YAG (neodymium-doped yttrium aluminum garnet) laser treatment of hidradenitis suppurativa (HS).

Interventions

  • Device Nd:YAG Laser
    Nd:YAG laser applied to one side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.
  • Device Alexandrite Laser
    Alexandrite laser applied to the contralateral side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.

Primary outcome measures

  • HiSCR50 [Time frame: 6 months]
  • HiSQOL [Time frame: 6 months]
Secondary outcome measures (4)
  • Pain VAS score [Time frame: 6 months]
  • Pruritus numeric rating scale [Time frame: 6 months]
  • Days free of disease in last 30 days [Time frame: 6 months]
  • AN Count [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • Geisinger male or female patients with a diagnosis of hidradenitis suppurativa (all stages of disease)
  • 12-75 years of age
  • Not on concurrent systemic therapy (e.g., antibiotics, biologic therapies)
  • Must have not used systemic therapies within 2 weeks of enrollment in study
  • Able and willing to provide consent

Exclusion criteria

  • Patients who cannot tolerate laser therapy
  • Patients who cannot wear protective eyewear
  • Patients who are pregnant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06960447 · 2024-0947

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗